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ARTICLE
Multiplexed in vivo homology-directed repair and
tumor barcoding enables parallel quantification of
Kras variant oncogenicity
Ian P. Winters 1, Shin-Heng Chiou1, Nicole K. Paulk 1,2, Christopher D. McFarland3, Pranav V. Lalgudi 1,
Rosanna K. Ma 1, Leszek Lisowski 2,4,5, Andrew J. Connolly6, Dmitri A. Petrov 3, Mark A. Kay1,2
& Monte M. Winslow 1,6,7,8
Large-scale genomic analyses of human cancers have cataloged somatic point mutations
thought to initiate tumor development and sustain cancer growth. However, determining the
functional significance of specific alterations remains a major bottleneck in our understanding
of the genetic determinants of cancer. Here, we present a platform that integrates multi-
plexed AAV/Cas9-mediated homology-directed repair (HDR) with DNA barcoding and high-
throughput sequencing to simultaneously investigate multiple genomic alterations in de novo
cancers in mice. Using this approach, we introduce a barcoded library of non-synonymous
mutations into hotspot codons 12 and 13 of Kras in adult somatic cells to initiate tumors in the
lung, pancreas, and muscle. High-throughput sequencing of barcoded KrasHDR alleles from
bulk lung and pancreas reveals surprising diversity in Kras variant oncogenicity. Rapid, cost-
effective, and quantitative approaches to simultaneously investigate the function of precise
genomic alterations in vivo will help uncover novel biological and clinically actionable insights
into carcinogenesis.
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A lthough somatic mutations in oncogenes typically clusterwithin a few specific residues, the resulting amino acidchanges can produce diverse oncogenic variants that have
dramatically different biochemical properties and which correlate
with distinct clinical outcomes1,2. The functional consequences of
specific oncogenic alterations have been investigated in cell lines
and in genetically engineered mouse models. Overexpression of
putative oncogenic variants in cell lines can uncover some aspects
of their function, but the interpretion of these studies is com-
plicated by the non-physiologic expression of variants, presence
of cell line-specific background alterations, and lack of a native
in vivo environment3. Conversely, tumors in genetically engi-
neered mice are driven by defined mutations expressed at phy-
siological levels and develop within their natural context. Tumors
initiated in these autochthonous mouse models also recapitulate
the gene expression programs and histopathological progression
of human cancers, including the development of invasive and
metastatic disease4. However, genetically engineered mouse
models are greatly limited by the time and cost associated with
their development and use4.
KRAS is the most frequently mutated oncogene in human
cancer5. Given the immense importance of oncogenic RAS pro-
teins in human cancer, and the renewed hope for therapeutics
targeting this family of proteins, there has been a resurgence of
interest in understanding the functional properties of diverse
oncogenic variants of RAS proteins6. KRAS commonly harbors
non-synonymous point mutations in codon 12 or 13 that result in
diverse amino acid substitutions. Interestingly, certain point
mutations in KRAS codon 12 or 13 are identified much more
frequently than others, which is thought to be a product of non-
uniform mutation rates as well as biological differences between
distinct oncogenic KRAS variants1,7,8.
Although conventional genetically engineered mice have been
used to model oncogenic KRAS-driven cancers, very few Kras
variants have been studied in autochthonous mouse models. For
instance, oncogenic KRAS-driven lung cancer has been almost
exclusively modeled using knock-in alleles in which Cre-mediated
or spontaneous recombination leads to KrasG12D expression9,10.
However, KRASG12D represents <20% of KRAS mutations in
human lung adenocarcinoma5,11. Nonetheless, data from
KrasG12D-based mouse models are often extrapolated to make
claims about “oncogenic KRAS” in general, while pre-clinical
studies performed in mice with KrasG12D-driven tumors may not
predict the response of all oncogenic KRAS-driven human
tumors. Our limited understanding of the in vivo oncogenicities
of even the most common variants of KRAS underscores the
fundamental and urgent need for rapid, quantitative, and precise
in vivo methods to model the diverse genetic alterations that
occur in human cancers.
CRISPR/Cas9-mediated somatic genome editing has recently
been used to rapidly investigate the function of tumor suppressor
genes in several autochthonous mouse models of cancer4,12.
Although the CRISPR/Cas9 system can be used to generate loss-
of-function mutations at targeted sites through error-prone non-
homologous end-joining, the addition of a homologous DNA
template permits the introduction of defined sequences at desired
sites through homology-directed repair (HDR). Cas9-mediated
HDR has enabled precise genomic editing in cell lines and
organoids, and HDR has also been used in mice to introduce
reporter genes, correct disease alleles, and introduce targeted
point mutations in several adult tissues4,12–17.
By circumventing the need to generate a new genetically
engineered mouse line for every oncogenic allele of interest, Cas9-
mediated HDR has the potential to provide an enormous decrease
in both the time and cost associated with modeling cancers with
defined oncogenic driver mutations in vivo. Here, we report a
method for efficient de novo cancer modeling in mice using
AAV/Cas9-mediated HDR. We demonstrate that this approach
enables multiplexed somatic HDR to produce genetically diverse
tumors within individual mice. Furthermore, while current
autochthonous cancer models rely on semiquantitative techni-
ques to assess tumor burden, we describe an HDR-based DNA
barcoding strategy that allows for quantitative tumor analyses
using high-throughput sequencing. The integration of AAV/
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Fig. 1 A cancer modeling platform that integrates AAV/Cas9-mediated somatic HDR with tumor barcoding and sequencing to enable the rapid
introduction and functional investigation of putative oncogenic point mutations in vivo. a–d Schematic of the pipeline to quantitatively measure the in vivo
oncogenicity of a panel of defined point mutations. a A library of AAV vectors is generated such that each AAV contains: (1) a template for homology-
directed repair (HDR) containing a putatively oncogenic point mutation and a random DNA barcode encoded in the adjacent wobble bases; (2) an sgRNA
targeting the desired endogenous locus to enhance HDR; and (3) Cre-recombinase to activate a conditional Cas9 allele (H11LSL-Cas9) and other Cre-
dependent alleles in genetically engineered mice. b The AAV library is delivered to a tissue of interest. c Following transduction, a subset of cells undergo
AAV/Cas9-mediated HDR in which the locus of interest is cleaved by Cas9 at the sgRNA target site and repaired using the AAV HDR template. This
results in the introduction of the desired point mutation and a unique DNA barcode at the targeted locus. d Somatic cells engineered with a point mutation
may develop into de novo tumors if the introduced mutation is sufficient to initiate tumorigenesis and drive tumor growth. Two independent approaches
can be used to analyze tumors: (1) the targeted region in individual tumors can be sequenced to characterize both alleles of the targeted gene, or (2) next-
generation sequencing of the targeted region can be used to determine the number, size, and genotype of each tumor directly from bulk tissue in a
quantitative and multiplexed manner
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Cas9-mediated HDR with tumor barcoding and deep sequencing
represents a novel platform to rapidly and quantitatively inter-
rogate the function of multiple precise mutations simultaneously
in mouse models of diverse human cancer types.
Results
AAV/Cas9-mediated HDR enables alteration of endogenous
Kras. To investigate the oncogenic function of diverse point
mutations in vivo in a quantitative and systematic manner, we
developed a platform for somatic AAV/Cas9-mediated HDR that
incorporates DNA barcoding and high-throughput sequencing in
autochthonous mouse models of several cancer types (Fig. 1). We
designed, generated, and validated a library of AAV vectors to
introduce all possible Kras codon 12 and 13 single-nucleotide
non-synonymous point mutations into somatic mouse cells in a
multiplexed manner (Fig. 2a–c and Supplementary Fig. 1). Each
AAV contained a ~2 kb Kras HDR template, a single-guide RNA
(sgRNA) targeting the second exon of Kras to enhance somatic
HDR, and Cre-recombinase (AAV-KrasHDR/sgKras/Cre; Fig. 2a
and Supplementary Fig. 1a)18.
The KrasHDR template contained the genomic sequence
flanking the second exon of Kras and either wild-type (WT)
Kras exon 2 or exon 2 with one of 12 single-nucleotide non-
synonymous mutations in codon 12 or 13 (Fig. 2a). Each KrasHDR
template also contained silent mutations within the sgKras target
sequence and associated protospacer adjacent motif (PAM*) to
prevent Cas9/sgKras-mediated cleavage of KrasHDR alleles (Fig. 2a
and Supplementary Fig. 1b, d). To enable the parallel quantifica-
tion of individual tumors by high-throughput sequencing of the
KrasHDR allele in DNA from bulk tissue, we diversified the
KrasHDR templates with a random barcode engineered into eight
wobble positions of the codons downstream of codons 12 and 13
(Fig. 2a and Supplementary Fig. 1b, c).
The AAV vectors also encoded Cre-recombinase, which
enabled tumor initiation in mice containing a Cre-regulated
Cas9 allele (H11LSL-Cas9)19 (Fig. 2a). Cre-recombinase also led to
labeling of transduced cells via a fluorescent Cre-reporter allele
(Rosa26LSL-Tomato)20 and enabled deletion of the tumor suppres-
sor genes p53 or Lkb1 using floxed alleles21,22. We packaged the
AAV-KrasHDR/sgKras/Cre library using an AAV8 capsid that
enables high titer production, efficient transduction of mouse
lung epithelial cells in vivo (Supplementary Fig. 2), and
transduction of a wide range of adult mouse tissues23.
We initially transduced Cas9-expressing cells in culture with
AAV-KrasHDR/sgKras/Cre to determine whether AAV/Cas9-
mediated HDR would be an unbiased method to engineer point
mutations into the endogenous Kras locus (Fig. 2d). We
developed a PCR strategy to specifically amplify KrasHDR alleles,
thus avoiding amplification of the endogenous Kras locus or any
residual episomal AAV-KrasHDR/sgKras/Cre (Fig. 2e). High-
throughput sequencing of the amplified KrasHDR regions from
transduced cells confirmed the generation of all point mutant
48 h
Cas9 MEFs
Extract DNA
PCR amplify 
Kras HDR events
Illumina® sequence
Quantify HDR
rate for each
Kras allele
AAV-KrasHDR/sgKras/Cre
Four cycles
35 cycles
F1
R1
F2
R2
R3
KrasWT
AAV-
KrasHDR
template
KrasHDR
allele
G12D
G12V
G12A
G12S
G12C
G12R
G13D
G13V
G13A
G13S
G13C
G13R
WT
2 4 8 16 32
2
4
8
16
32
Plasmid library reads (%)
In
 v
itr
o 
H
D
R
 re
ad
s 
(%
)
%
G12D
G12V
G12A
G12S
G12C
G12R
G13D
G13V
G13A
G13S
G13C
G13R
9.6
4.1
4.7
7.9
3.8
4.8
9.6
2.8
3.7
8.4
4.8
4.4
31.2WT
N G G N A A R T C N G C N C T N A C N A T H
0
20
40
60
80
100
Barcode
Pe
rc
en
t o
f r
ea
ds
A TC G
ITR ITRKrasHDR (2.1 kb) PGK-Cre
U6-sgKras
G12 G13
PAM*
AGTAGTCGTTGGAGCTGGTGGCGTNGGNAARTCNGCNCTNACNATH 
Exon 2
GATGGCGTTGGCGCTGGCAGTGGCTGTGGCCGTGGCGGTGACGGTGTCGGTGCCGGTAGCGGTTGCGGTCGC
G12D
G12V
G12A
G12S
G12C
G12R
G13D
G13V
G13A
G13S
G13C
G13R
Barcode
KrasHDR
allele
R2 = 0.9986
a b c
d e f
Fig. 2 Design and validation of an AAV targeting vector library to introduce all Kras codon 12 and 13 single-nucleotide non-synonymous point mutations
into somatic mouse cells in a multiplexed manner. a AAV vector pool for Cas9-mediated HDR into the endogenous Kras locus (AAV-KrasHDR/sgKras/Cre).
Each vector contained an HDR template with 1 of 12 non-synonymous Kras mutations at codons 12 and 13 (or wild-type Kras), silent mutations within the
PAM (boxed sequence) and sgRNA homology region (PAM*), and a random 8-nucleotide barcode within the wobble positions of the adjacent codons for
stable DNA barcoding of individual tumors. b Representation of each KrasHDR allele in the AAV-KrasHDR/sgKras/Cre plasmid library. c Diversity of the
barcode region in the AAV-KrasHDR/sgKras/Cre plasmid library. d Schematic of the experiment to test for HDR bias. A Cas9-expressing cell line was
transduced with AAV-KrasHDR/sgKras/Cre and KrasHDR alleles were sequenced to quantify HDR events. e Schematic of the PCR strategy to specifically
amplify KrasHDR alleles introduced into the genome via HDR. Forward primer 1 (F1) binds to the sequence containing the 3 PAM* mutations, while reverse
primer 1 (R1) binds the endogenous Kras locus, outside the sequence present in the homology arm of the KrasHDR template. F2 binds to the Illumina adaptor
added by F1, R2 binds to a region near exon 2, and R3 binds to the Illumina adapter added in the same reaction by R2. f Frequency of HDR events for each
KrasHDR allele plotted against the initial frequency of each Kras mutant allele in the AAV-KrasHDR/sgKras/Cre plasmid library. High correlation between the
initial plasmid library and the representation of mutant Kras alleles following HDR suggests little to no HDR bias
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Kras alleles. The representation of KrasHDR alleles in these cells
was highly correlated with their representation in the plasmid
library, suggesting that HDR using our AAV vector was not
discernably biased by any single-nucleotide Kras codon 12 or 13
point mutation in the KrasHDR template (Fig. 2f). Therefore, any
differential expansion of tumors harboring specific Kras mutant
alleles in vivo could be attributed to differences in the
oncogenicity of Kras variants rather than HDR bias.
Somatic HDR initiates mutant Kras-driven lung tumors
in vivo. To determine whether HDR in somatic cells could
initiate tumors, and to investigate whether Kras variants differ in
their ability to drive tumorigenesis, we delivered the AAV-
KrasHDR/sgKras/Cre library intratracheally to the lungs of mice
with the H11LSL-Cas9 allele (Fig. 3a and Supplementary Fig. 3a).
Three different genotypes of mice were transduced to provide
additional insight into whether concurrent inactivation of tumor
suppressor genes modulates Kras variant oncogenicity: (1)
Rosa26LSL-Tomato;H11LSL-Cas9 (T;H11LSL-Cas9) mice, (2) p53flox/flox;
T;H11LSL-Cas9 (PT;H11LSL-Cas9) mice in which tumors would lack
p53, and (3) Lkb1flox/flox;T;H11LSL-Cas9 (LT;H11LSL-Cas9) mice in
which tumors would lack Lkb1 (Fig. 3a and Supplementary
Fig. 3a).
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Fig. 3 AAV/Cas9-mediated somatic HDR initiates oncogenic Kras-driven lung tumors. a Schematic of the experiment to introduce point mutations and a
DNA barcode into the endogenous Kras locus of lung epithelial cells in Rosa26LSL-Tomato;H11LSL-Cas9 (T;H11LSL-Cas9), p53flox/flox;T;H11LSL-Cas9 (PT;H11LSL-Cas9),
and Lkb1flox/flox;T;H11LSL-Cas9 (LT;H11LSL-Cas9) mice by intratracheal administration of AAV-KrasHDR/sgKras/Cre (8.4 × 1010 vector genomes per mouse).
b Representative fluorescence and histology images of Tomatopositive lung tumors in LT;H11LSL-Cas9, PT;H11LSL-Cas9, and T;H11LSL-Cas9 mice transduced with
AAV-KrasHDR/sgKras/Cre. Scale bars= 5mm. c Quantification of lung tumors in the indicated genotypes of mice transduced with the indicated AAV
vectors (with and without sgKras). Each dot represents one mouse. d Representative FACS plot showing Tomatopositive DTCs in the pleural cavity of an LT;
H11LSL-Cas9 mouse with AAV-KrasHDR/sgKras/Cre-initiated lung tumors. Plot shows forward scatter/side scatter (SSC)-gated viable cancer cells (DAPI/
CD45/CD31/F4-80/Ter119negative). e Histology of lymphatic metastases from AAV-KrasHDR/sgKras/Cre-initiated lung tumors in PT;H11LSL-Cas9 mice. Scale
bar= 50 µm. f Number of AAV-KrasHDR/sgKras/Cre-transduced mice of each genotype that had disseminated tumors cells in their pleural cavity (DTCs>
10) or metastases out of the total number of mice analyzed. g KrasLSL-G12D/+;LT (KLT) and KrasLSL-G12D/+;PT (KPT) mice transduced with a 1:10,000 dilution
of AAV-KrasHDR/sgKras/Cre developed approximately half as many tumors as the PT;H11LSL-Cas9 and LT;H11LSL-Cas9 mice transduced with undiluted virus. If
all KrasHDR alleles in the AAV-KrasHDR/sgKras/Cre library are oncogenic, this suggests that AAV/Cas9-mediated HDR occurs in ~0.02% of transduced
cells. Alternatively, if only 20% of the mutant alleles in the AAV-KrasHDR/sgKras/Cre library are oncogenic, this suggests that HDR occurs in ~0.1% of
transduced cells. h Diverse HDR-generated oncogenic Kras alleles in individual lung tumors dissected from LT;H11LSL-Cas9 and PT;H11LSL-Cas9 mice
transduced with AAV-KrasHDR/sgKras/Cre. Number of tumors with each allele is indicated. Alleles that were not identified in any lung tumors are not
shown. For the KrasHDR alleles identified, Bonferroni corrected p values for likelihood of enrichment relative to WT are shown (Fisher’s exact test
generalized for structural zeros; see Methods section)
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LT;H11LSL-Cas9 mice were the first to show signs of tumor
development including tachypnea and weight loss between 5 and
7 months after AAV administration. This is consistent with the
rapid growth of lung tumors initiated in mice with a Cre-
regulated KrasG12D allele and floxed Lkb1 alleles24–26. LT;H11LSL-
Cas9 mice had many large primary lung tumors, resulting in high
tumor burden (Fig. 3b, c and Supplementary Fig. 3b–d).
Histological analysis confirmed the presence of large adenomas
and adenocarcinomas in these mice (Fig. 3b and Supplementary
Fig. 3b). PT;H11LSL-Cas9 mice also developed numerous large
primary lung tumors 6–8 months after viral transduction.
Compared to the LT;H11LSL-Cas9 mice, tumors initiated in PT;
H11LSL-Cas9 mice had more pronounced nuclear atypia, a
characteristic feature of p53 deficiency27. Finally, T;H11LSL-Cas9
mice developed smaller, less histologically advanced lesions, even
at later time points (>10 months after tumor initiation; Fig. 3b, c
and Supplementary Fig. 3b–d). Mice transduced with a 10-fold
lower titer of AAV-KrasHDR/sgKras/Cre developed proportionally
fewer tumors (Supplementary Fig. 3e). Importantly, delivery of an
analogous AAV vector without sgKras (AAV-KrasHDR/Cre) to T,
PT, and LT mice did not lead to efficient tumor initiation (Fig. 3c
and Supplementary Fig. 4). This indicates that neither p53 nor
Lkb1 deficiency, combined with high-level AAV vector transduc-
tion, is sufficient to drive lung tumorigenesis. Several LT;H11LSL-
Cas9 and PT;H11LSL-Cas9 mice with AAV-KrasHDR/sgKras/Cre-
initiated tumors developed invasive primary lung tumors, had
disseminated tumor cells (DTCs) in their pleural cavities, and had
lymph node metastases (Fig. 3d–f). Thus, AAV-KrasHDR/sgKras/
Cre-induced tumors can progress into malignant and metastatic
lung cancer.
To approximate the efficiency of somatic HDR in lung
epithelial cells in vivo, we compared the number of lung tumors
initiated by AAV-KrasHDR/sgKras/Cre in mice containing the
H11LSL-Cas9allele (in which Kras would be activated by HDR) to
the number of lung tumors initiated in KrasLSL-G12D mice
(in which Kras would be activated by Cre; Fig. 3g). We
transduced KrasLSL-G12D/+;PT and KrasLSL-G12D/+;LT mice with
a 1:10,000 dilution of AAV-KrasHDR/sgKras/Cre (Fig. 3g). These
mice developed approximately half as many tumors as mice in
which oncogenic Kras alleles were generated by AAV/Cas9-
mediated somatic HDR after transduction of lung epithelial cells
with undiluted AAV-KrasHDR/sgKras/Cre (Fig. 3g). This result is
consistent with an HDR frequency between 0.02 and 0.1%
(Fig. 3g). Importantly, this rate of HDR combined with the high-
transduction efficiency of AAV enables the parallel initiation of
numerous lung tumors within individual mice (Fig. 3c).
To determine whether tumors initiated using AAV-KrasHDR/
sgKras/Cre harbored mutant KrasHDR alleles, we analyzed the
Kras locus in cancer cells from large, individual lung tumors from
LT;H11LSL-Cas9 and PT;H11LSL-Cas9 mice (Fig. 3c). PCR ampli-
fication using primers specific to the KrasHDR allele confirmed the
presence of an oncogenic Kras allele with a unique barcode in
each tumor (Figs. 2e, 3h). Interestingly, only five Kras variants
were identified in ~50 large lung tumors, consistent with
differential selection of Kras variants in lung tumorigenesis
(Fig. 3h).
By analyzing individual tumors, we were able to carefully assess
the KrasHDR allele as well as the second Kras allele in each tumor
(Supplementary Fig. 5). Approximately half of the oncogenic
KrasHDR alleles resulted from perfect HDR events in which a Kras
DTCs
AAV-KrasHDR/
sgKras/Cre
PT;H11LSL-Cas9
MetsPDAC
AAV-KrasHDR/
Cre
2/2 1/1 2/2
0/4 N/a N/aPT
T 0/1 N/a N/a
PT;H11LSL-Cas9 1/4 N/a 0/4
Undil.
1:10 G12D
G12V
Total
Pancreas
KrasHDR
allele
KrasHDR
P
T
;H
11
LS
L-
C
as
9
3
4
1
4
H&E
H&E
H&E
Undil.
Undil.
H&E
PT;H11LSL-Cas9
AAV-KrasHDR/sgKras/Cre
3–4
months
Virus
dilution
Mouse
genotypeVirus
Retrograde pancreatic
ductal injection
a b c
d e
I W 111
9
Fig. 4 Introduction of mutant Kras variants into pancreatic cells using AAV/Cas9-mediated HDR drives the formation of metastatic PDAC. a Schematic of
retrograde pancreatic ductal injection of AAV-KrasHDR/sgKras/Cre (∼1.7 × 1011 vector genomes per mouse) into PT;H11LSL-Cas9 mice to induce pancreatic
cancer. b Histology of pancreatic tumors initiated by retrograde pancreatic ductal injection of AAV-KrasHDR/sgKras/Cre into PT;H11LSL-Cas9 mice. Scale
bars= 75 µm. c Histology of metastases in the lymph node (upper panel) and diaphragm (lower panel) in PT;H11LSL-Cas9 mice with PDAC. Scale bars= 50
µm. d Incidence of PDAC, DTCs in the peritoneal cavity, and metastases in the indicated genotypes of mice (shown as the number of mice with cancer,
DTCs, or metastases out of the total number of mice analyzed), 3–13 months after transduction with either AAV-KrasHDR/sgKras/Cre or AAV-KrasHDR/Cre
(∼2.9 × 1011 vector genomes per mouse). AAV-KrasHDR/sgKras/Cre was administered at the stock concentration (“undil.”) or at a 1:10 dilution (“1:10”).
e HDR-generated oncogenic Kras alleles in individually dissected pancreatic tumor masses. Number of tumors with each allele is indicated. Alleles that
were not identified in any pancreatic tumor masses are not shown
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01519-y ARTICLE
NATURE COMMUNICATIONS |8:  2053 |DOI: 10.1038/s41467-017-01519-y |www.nature.com/naturecommunications 5
point mutation and a unique barcode were seamlessly recom-
bined into the endogenous Kras locus. The remaining KrasHDR
alleles were seamless from the 5′ end through mutant exon 2, but
contained small duplications, insertions, or deletions in intron 2
(Supplementary Fig. 5). Importantly, none of these alterations
would be expected to disrupt splicing from mutant exon 2 into
exon 3. Additionally, almost all tumors harbored Cas9-induced
indels in the second Kras allele, which is consistent with the loss
of the wild-type KRAS allele observed in some oncogenic KRAS-
driven human tumors (Supplementary Fig. 6)28,29. While
previous studies have documented enhanced KrasG12D- and
KrasQ61L-driven lung tumor growth following inactivation of the
wild-type Kras allele in mice30,31, our results suggest that wild-
type Kras may suppress the growth of lung tumors driven by
many different oncogenic Kras variants.
Somatic HDR can initiate pancreatic cancer. In addition to
driving human lung cancer, oncogenic KRAS mutations are
nearly ubiquitous in human pancreatic ductal adenocarcinoma
(PDAC)32. Furthermore, genomic and clinical data from PDAC
patients indicate that KRAS variants differentially impact down-
stream signaling as well as patient prognoses32,33. Expression of
KrasG12D or KrasG12V in pancreatic cells of genetically engineered
mice drives widespread formation of pancreatic intra-epithelial
neoplasias (PanINs), but rarely leads to PDAC within 1
year32,34,35. However, KrasG12D or KrasG12V expression in mouse
pancreatic cells combined with p53mutation—a frequent event in
human PDAC—reliably leads to the development of PDAC35.
Thus, to determine whether AAV/Cas9-mediated somatic
HDR could also induce cancer-initiating oncogenic point
mutations in pancreatic epithelial cells, we transduced PT;
H11LSL-Cas9 mice with AAV-KrasHDR/sgKras/Cre by retrograde
pancreatic ductal injection (Fig. 4a and Supplementary Fig. 7a)19.
These mice developed PanINs as well as PDAC (Fig. 4b and
Supplementary Fig. 7b, c). Several mice also developed metastatic
PDAC, consistent with the aggressive nature of the human
disease (Fig. 4c, d and Supplementary Fig. 7d, e). Sequencing of
KrasHDR alleles from several individual pancreatic tumor masses
uncovered oncogenic KrasG12D and KrasG12V alleles with unique
barcodes (Fig. 4e). Consistent with the requirement for oncogenic
Kras to initiate PDAC, transduction of pancreatic cells in PT mice
by retrograde pancreatic ductal injection of our negative control
AAV-KrasHDR/Cre vector did not induce any pancreatic tumors
(Fig. 4d).
HDR in somatic skeletal muscle cells induces sarcoma. The
history of the RAS oncogenes began with their identification as
the transforming factors in retroviruses capable of inducing rat
sarcoma (hence, RAS)36. Human sarcomas are a highly hetero-
geneous cancer type comprised of over 50 histological subtypes
that arise from many tissue and cell types37. Soft tissue sarcomas
harbor diverse genomic alterations, including recurrent mutations in
the tumor suppressor TP53 as well as the RAS pathway components
NF1, PTEN, and PIK3CA38,39. Although KRAS is infrequently
mutated in sarcomas, KRAS mutations occur in undifferentiated
pleomorphic sarcomas as well as in rhabdomyosarcomas, which
account for nearly half of pediatric soft tissue sarcomas37,40–42.
Importantly, sarcomas have been induced in genetically engineered
mouse models through the expression of KrasG12D and inactivation
of p5337,38,43,44. However, generating mouse models of soft tissue
sarcoma remains a challenge given the genetic diversity of the dis-
ease, and methods to rapidly model oncogene mutations in sarco-
magenesis have not been described37,44.
To determine whether AAV/Cas9-mediated somatic HDR
could be used to introduce point mutations into Kras and
drive sarcoma formation, we performed intramuscular
injections of AAV-KrasHDR/sgKras/Cre into the gastrocnemii of
PT;H11LSL-Cas9 mice (Fig. 5a and Supplementary Fig. 8a). These
mice developed rapidly growing and invasive skeletal muscle
sarcomas that harbored uniquely barcoded oncogenic KrasG12D,
KrasG12A, or KrasG13R alleles (Fig. 5b–e and Supplementary
Fig. 8b–d). The successful application of this platform for
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modeling tumorigenesis in diverse tissues highlights its broad
applicability for multiplexed functional analyses of oncogenic
driver mutations in a wide range of cancer types.
Tumor barcode sequencing reveals Kras variant oncogenicity.
Whereas conventional methods to assess the effects of different
genomic alterations in autochthonous cancer models largely rely
on manual quantification of tumor number and size, we recently
established a simple yet high-throughput approach to determine
the genotype and number of neoplastic cells within individual
tumors directly from bulk tissue by tumor barcoding and
sequencing (Tuba-seq)26. Here, we extended the Tuba-seq plat-
form to enable multiplexed and quantitative measurements of
HDR-initiated tumors in vivo by engineering a random barcode
into the wobble bases adjacent to an activating point mutation of
interest. Since neoplastic cells within AAV-KrasHDR/sgKras/Cre-
initiated tumors each contain a copy of the same unique DNA
barcode, the relative number of neoplastic cells within each tumor
can be determined by deep sequencing of the barcode region
(Figs. 1d, 6a). Furthermore, by adding a normalization control
consisting of a known number of cells with a known barcode to
each bulk tissue sample prior to sequencing, the absolute number
of neoplastic cells in each tumor can be estimated from relative
sequencing read counts26. To determine the Kras genotype and
number of neoplastic cells in each tumor in T;H11LSL-Cas9, PT;
H11LSL-Cas9, and LT;H11LSL-Cas9 mice, we added a normalization
control consisting of DNA from 5 × 105 cells with a known
barcode to each lung sample (Fig. 6a and Supplementary Fig. 9).
We then extracted DNA from each sample, PCR-amplified the
KrasHDR alleles, and deep-sequenced the variant-barcode region
(Fig. 6a and Supplementary Fig. 9).
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Following high-throughput sequencing, we corrected for
recurrent sequencing errors and the possibility of individual
tumors having identical barcodes (see Methods section). We then
estimated the absolute number of neoplastic cells in each tumor
by normalizing tumor barcode-sequencing read counts to the
number of reads from the normalization control DNA. This
analysis pipeline was exceptionally reproducible with a high
degree of concordance in tumor sizes across technical replicates
(Supplementary Fig. 10).
High-throughput sequencing of the KrasHDR variant-barcode
region uncovered many AAV-KrasHDR/sgKras/Cre-induced lung
tumors in T;H11LSL-Cas9, PT;H11LSL-Cas9, and LT;H11LSL-Cas9
mice (Supplementary Fig. 11 and Supplementary Data 1).
Normalizing tumor number to the initial representation of each
KrasHDR allele in the AAV-KrasHDR/sgKras/Cre vector library
allowed us to directly compare the in vivo oncogenicity of
each Kras variant (Fig. 6b–e, Supplementary Fig. 11d, e, and
Supplementary Data 2). Across >500 tumors, KrasG12D was the
most common variant, consistent with KRASG12D being the most
frequent KRAS mutation in human lung adenocarcinoma in
never-smokers45. KrasG12A, KrasG12C, and KrasG12V—the next
most frequent KRAS variants in lung adenocarcinoma in never-
smokers after KRASG12D—were identified as moderate drivers of
lung tumorigenesis, but were present in fewer tumors than
KrasG12D (Fig. 6b–e and Supplementary Fig. 11a–e). Interestingly,
KrasG12R and KrasG13R were also identified as potent oncogenic
variants, despite being infrequently mutated in human lung
cancer (Fig. 6b–e and Supplementary Fig. 11a–e).
Kras expression can be influenced by overall changes in codon
usage46,47. As our barcoding approach changed up to eight
codons, we investigated whether alterations in Kras codon usage
influenced tumor size. By calculating the relative change in codon
usage introduced by each unique barcode, we found that the
degree to which overall codon usage increased or decreased did
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not correlate with tumor size (Supplementary Fig. 12)48. There
was also no bias toward increased or decreased codon usage in the
tumors identified (Supplementary Fig. 12).
Kras oncogenicity is robust to tumor suppressor inactivation.
We initiated tumors in LT;H11LSL-Cas9, PT;H11LSL-Cas9, and T;
H11LSL-Cas9 mice to directly assess whether concurrent tumor
suppressor alterations modulate the ability of different Kras
variants to initiate and drive tumor growth. In general, Lkb1-
deficient tumors from LT;H11LSL-Cas9 mice grew much more
rapidly than tumors in PT;H11LSL-Cas9 and T;H11LSL-Cas9 mice
(Supplementary Fig. 3a–d). Surprisingly, no statistically sig-
nificant pairwise deviations in tumor number were observed for
any Kras variant across tumors with different tumor suppressor
genotypes. However, by considering the aggregate deviations in
Kras variants across genotypes, we observed subtle differences in
the spectrum of Kras variants in Lkb1-deficient tumors compared
to p53-deficient or otherwise wild-type tumors (Supplementary
Fig. 11f). These data are consistent with a model in which the
strength of signaling induced by these oncogenic Kras variants
in vivo is insufficient to engage the p53 pathway; thus, while p53
functions to constrain tumor progression, it does not appear to
limit the initial expansion of tumors with different Kras geno-
types49. Additionally, while Lkb1 deficiency increased tumor
growth, in general, Lkb1 deficiency did not appear to pre-
ferentially synergize with any specific oncogenic Kras variants
(Fig. 6c–e and Supplementary Figs. 3d and 11a–e).
Tuba-seq enables mapping of pancreatic tumors and metas-
tases. Since our tumor barcoding and sequencing platform
(Tuba-seq26) allowed us to characterize many individual tumors
in parallel from bulk lungs, we anticipated that we could also use
this approach to overcome the challenge of identifying and ana-
lyzing individual pancreatic tumor clones in multifocal tumor
masses initiated in autochthonous mouse models19. Therefore, we
analyzed bulk pancreatic tumor samples from PT;H11LSL-Cas9
mice transduced with AAV-KrasHDR/sgKras/Cre (Fig. 7a and
Supplementary Fig. 13a). Barcode sequencing of pancreatic tumor
masses uncovered multiple primary tumor clones per mouse,
each harboring a KrasHDR allele with a unique DNA barcode
(Fig. 7b and Supplementary Data 3). Pancreatic tumors demon-
strated oncogenic Kras allele preferences with KrasG12D,
KrasG12V, and KrasG12R being significantly enriched (Fisher’s
exact test; Fig. 7b). Notably, these three Kras variants are also the
most prevalent oncogenic KRAS mutations in human PDAC50.
In addition to determining the in vivo oncogenicity of specific
Kras variants, our barcode-sequencing approach allowed us to
identify contiguous tumor clones from multi-region sequencing
of PDAC masses (Fig. 7c and Supplementary Fig. 13b). Finally,
using barcode sequencing we were able to uncover clonal
relationships between primary tumors and their metastatic
descendants (Fig. 7c and Supplementary Fig. 13b).
Discussion
Prior to the introduction of massively parallel sequencing, one of
the most profound challenges in the field of cancer biology was
the identification of genomic alterations in human cancers51.
Over the past decade, next-generation sequencing technologies
have been leveraged to catalog millions of somatic mutations in
human cancer52. With this quantum leap in our understanding of
the genomic landscape of human tumors, the burden of progress
now rests squarely on our ability to uncover the biological
function of cancer-associated mutations. The increasing need for
faster, more economical, and higher-throughput functional
genomics strategies has found a measure of relief with the
emergence of CRISPR/Cas9-based genome-editing technologies.
The ability to directly modify the genomes of somatic cells in
adult mice represents a substantial advance in cancer modeling,
enabling the interrogation of gene function in de novo tumors at
only a fraction of the time and cost of conventional systems4,12.
Methods to deliver Cas9 and a sgRNA to somatic cells,
including transfection and viral transduction techniques, facilitate
the generation of tumors harboring putative tumor suppressor
gene alterations that have yet to be functionally studied in vivo12.
The delivery of pools of sgRNAs to introduce multiple somatic
loss-of-function mutations in parallel represents another critical
milestone on the path to more rapid and higher-throughput
studies of the functional consequences of mutations in can-
cer26,53,54. Here, we add multiplexed AAV/Cas9-mediated
somatic HDR to the cancer modeling toolkit, further expanding
the realm of cancer genotypes that can be easily studied in vivo
(Fig. 1). We demonstrate that somatic HDR is a quantitative,
scalable, and modular approach for systematic studies of the
functional consequences of panels of oncogene mutations in
parallel. Using this approach, we rapidly modeled tumors of
multiple genotypes in several diverse tissues in vivo. Importantly,
this method can be readily integrated with conventional geneti-
cally engineered mouse models including those with floxed and
reporter alleles. Additionally, as genome engineering strategies
continue to facilitate higher-content functional screens in auto-
chthonous cancer models, the lack of correspondingly high-
throughput methods for tumor analysis has emerged as a fun-
damental bottleneck in the functional annotation of cancer
genomics data. To hurdle this barrier, we integrated a DNA
barcoding strategy into our somatic HDR platform to enable the
use of next-generation sequencing to determine the number, size,
and genotype of tumors directly from bulk tissue in a quantitative
and multiplexed manner (Fig. 1).
Using this HDR platform, we investigated the functional
consequences of KRAS point mutations, which are among the
most common driving events in human cancer55. Our study
addresses the fundamental question of whether tumorigenesis
driven by specific KRAS mutations results in different patholo-
gical outcomes—indeed, we identify dramatic differences in the
oncogenicity of Kras variants in vivo. The elucidation of these
quantitative differences in oncogenic potential should facilitate
the reclassification and therapeutic stratification of KRAS-driven
tumors based on the functional consequences of specific KRAS
variants, and contribute to the renewed effort to understand
somatic cancer mutations at the level of the nucleotide rather
than the gene.
Biochemical differences between KRAS variants as well as the
frequency with which certain nucleotide substitutions in KRAS
are generated likely both contribute to the non-uniform dis-
tribution of KRAS variants in human tumors. In vitro experi-
ments have uncovered biochemical, structural, and cell context-
specific differences between KRAS variants that could serve as
biological substrates for tumorigenic selection. Notably, 98% of
KRAS mutations in human tumors affect active site residues, thus
limiting GTPase activity1,55. However, despite measurable dif-
ferences in both the intrinsic and GAP-mediated GTPase activity
of KRAS variants, neither biochemical property correlates with
in vivo oncogenicity (Supplementary Fig. 14)2. Oncogenic pro-
clivity was also not well-predicted by affinity for RAF, although
variants with relatively low RAF affinities (KrasG12D, KrasG12V,
and KrasG12R) tended to be more oncogenic in our models of
lung and pancreatic cancer (Supplementary Fig. 14c, f)2. Collec-
tively, these data suggest that the in vivo oncogenicity of KRAS
variants may be better described either by an alternate bio-
chemical property, or more likely, through the integration of
multiple biochemical inputs.
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Though the biochemical mechanisms remain unclear, our data
indicate that the primary determinant of mutant KRAS repre-
sentation in human PDAC is likely of a biological rather than
etiological origin; we identified KrasG12D, KrasG12V, and
KrasG12R as the most potent drivers of PDAC in vivo, which
together account for >90% of all KRAS mutations in human
PDAC (Fig. 7b, Supplementary Fig. 15, and Supplementary
Data 4). This conclusion is supported by autochthonous zebrafish
models of Kras-induced pancreatic tumorigenesis, and suggests
that the cells of origin of PDAC may not be subjected to the same
levels of mutagenic bias that afflict tissues such as the lung whose
mutational burden can be more directly linked to specific external
factors55–58.
The forces driving the spectrum of KRAS mutations in human
lung cancer appear to be less centralized than in cancers of the
pancreas. Differences between the oncogenicity of specific Kras
variants in our mouse model compared to their prevalence in
human lung cancers indicate that factors other than the intrinsic
oncogenicity of KRAS mutants likely influence their representa-
tion in the human disease. Although KrasG12D, KrasG12C,
KrasG12V, and KrasG12A were enriched in lung tumors in mice—
as they are in humans—KrasG12C was less frequent than expected
given the spectrum of KRAS mutations in the human disease,
while KrasG12R and KrasG13R were more frequent (Fig. 6b, Sup-
plementary Fig. 15, and Supplementary Datas 2 and 4).
The high prevalence of KRASG12C in human lung cancer is
largely driven by the mutational processes that lead to lung cancer
initiation. Indeed, numerous studies have identified mutational
signatures in the lung cancer genome that represent extant
records of the tumor’s etiological origins56,58,59. By examining the
biases associated with tumor-extrinsic mutational signatures58—
including the smoking-related signature and the molecular clock-
like signature—we estimate that KRASG12C is approximately five
times more likely than KRASG12D to occur in the cells of origin of
lung adenocarcinomas (Supplementary Fig. 16a and Supple-
mentary Data 5). Furthermore, whereas KRASG12C is the most
frequent KRAS mutation in lung adenocarcinomas in current/
former-smokers, it is approximately three times less prevalent in
never-smokers in which KRASG12D is the dominant mutation
(Supplementary Fig. 16b and Supplementary Data 6)45,58,59.
These results underscore the importance of a holistic view of
mutational prevalence in human cancer with careful considera-
tion for the mechanisms underlying both the formation and
function of somatic cancer mutations.
Neither mutational biases nor biochemical properties appear to
fully explain why KrasG12R and KrasG13R were identified as
potent drivers of lung tumorigenesis in mice but are rare in
human lung adenocarcinomas (Fig. 6b, Supplementary Fig. 15,
and Supplementary Datas 2 and 4). Existing structural, bio-
chemical, in vitro, and in vivo data might compel one to believe
that these two variants are indeed oncogenic. Arginine substitu-
tions at KRAS residue 12 or 13 prevent formation of transition
state complexes with GAPs—an interaction that stimulates the
minimal intrinsic GTPase activity of wild-type KRAS by
approximately five orders of magnitude1,60. KrasG12R has a lower
GAP-mediated GTPase activity than either KrasG12C or
KrasG12D1. KRASG12R expression also leads to cellular transfor-
mation in culture, and drives de novo tumor formation in the
lung and pancreas in various autochthonous systems (Figs. 6b,
7b)57,61. Human cancer genomics data also provides evidence of
the oncogenicity of G12R and G13R substitutions in RAS pro-
teins: KRASG12R accounts for >10% of KRAS-driven PDACs
(Supplementary Fig. 15c and Supplementary Data 4), while
HRASG13R is the fourth most frequent HRAS mutation in human
cancers and NRASG13R is common in colorectal cancers1,8,62.
Taken together, these data warrant a shift in perspective from the
conundrum of why these variants are so oncogenic in our model
to the question of why they are not in people.
The answer may lie with one, or perhaps many, of the myriad
variables that define the molecular, cellular, and environmental
context within which a tumor forms. A simple explanation could
be species-specific effects. Although mouse and human KRAS
orthologs share 97% (183/188) amino acid identity, the amino
acid mismatches are concentrated in the C-terminal hypervari-
able region (HVR) of KRAS (Supplementary Fig. 17). The RAS
HVR regulates the subcellular trafficking and localization, post-
translational modification, and effector binding of RAS pro-
teins1,63. Additionally, species-specific regulatory mechanisms
could differentially modulate the expression of endogenous KRAS
as well as its effectors46,48,64. This is a particularly important
consideration since the functional consequences of oncogenic
RAS proteins are highly dependent on their expression; too little
RAS signaling is non-transforming, while chronic, moderate
levels of RAS are highly transforming, and hyperactive RAS sig-
naling can lead to cellular senescence or growth arrest34,49,64,65.
This is suggestive of a “Goldilocks Model of Oncogenicity” in
which KRAS variants, such as KRASG12R or KRASG13R, conduct
either too little or too much RAS signaling in human lung epi-
thelial cells to effectively drive sustained tumorigenesis. Interest-
ingly, while this model may have predicted that p53 deficiency
would enable some otherwise “too strong” Kras variants to drive
tumor formation, this was in fact not the case in our study.
Finally, the identification of increasing numbers of cancer sus-
ceptibility loci using both in vivo and in silico approaches indicate
that epistatic interactions between KRAS and genetic modifiers
represent another intriguing contributor to KRAS mutant
oncogenicity61,66.
The key insights of our study are twofold: (1) amino acid
substitutions in Kras residues 12 and 13 have quantitatively dif-
ferent and cancer type-dependent abilities to drive tumorigenesis
and (2) both the functional consequences of specific Kras muta-
tions, as well as the mechanisms leading to their initiation, play
major roles in determining their pervasiveness in human cancer.
Multiplexed approaches that enable the genetic dissection of RAS
function in vivo represent a valuable complement to ongoing
computational, biochemical, and cell culture-based studies of
mutant forms of RAS proteins6. Notably, despite mounting evi-
dence that cancers harboring different KRAS mutations can have
differential therapeutic responses, the singular genetic inclusion
criterion of “confirmed KRAS mutation” is listed for the vast
majority of clinical trials in patients with KRAS-driven tumors.
The development and application of novel strategies to more
rapidly interrogate the functional consequences of defined cancer
mutations will undoubtedly redefine our biological and clinical
understanding of many cancers types. We envision that this
CRISPR-based somatic HDR platform will enable an unprece-
dented understanding of the function of common and rare
mutations in oncogenes across diverse cancer types, and will
dramatically accelerate both the discovery and pre-clinical vali-
dation of therapies for precisely defined genetic subtypes of
cancer.
Methods
Design, generation, and screening of sgRNAs targeting Kras. To obtain an
sgRNA targeting Kras to enhance HDR in somatic mouse cells, we identified all
possible 20 bp sgRNAs (using the consensus Cas9 PAM: NGG) targeting Kras exon
2 and the flanking intronic sequences, and scored them for predicted on-target
cutting efficiency using an available sgRNA design/scoring algorithm67. We then
empirically determined the cutting efficiency of three sgRNAs targeting Kras
(sgKras#1: GCAGCGTTACCTCTATCGTA; sgKras#2: GCTAATTCA-
GAATCACTTTG; sgKras#3: GACTGAGTATAAACTTGTGG) (Supplementary
Fig. 1a). Briefly, Lenti-U6-sgRNA/Cre vectors were generated for each sgRNA
targeting Kras as previously described4. Q5® site-directed mutagenesis (NEB)
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was used to insert the sgRNAs into a parental lentiviral vector containing a U6
promoter to drive sgRNA transcription as well as a PGK promoter to drive
Cre-recombinase. The cutting efficiency of each sgKras was determined via
transduction of LSL-YFP;Cas9 cells in culture with each Lenti-sgKras/Cre virus. We
isolated YFPpositive cells 48 h post transduction by fluorescence-activated cell
sorting (FACS), extracted DNA, PCR-amplified the targeted Kras locus (forward
primer: TCCCCTCTTGGTGCCTGTGTG; reverse primer: AAGCCCTTCCTGC-
TAATCTCGGAG), and Sanger-sequenced the amplicons (sequencing primer:
GCACGGATGGCATCTTGGACC). Sequencing traces were analyzed by TIDE
(tracking of indels by decomposition) to determine percent indel induction68. Since
all three sgRNAs induced indels at the anticipated loci, the sgKras targeting the
sequence closest to Kras codons 12 and 13 (sgKras#3) was used for all subsequent
experiments as this was expected to best facilitate HDR at the desired locus
(Supplementary Fig. 1a).
AAV-KrasHDR library design, construction, and validation. The U6-sgKras/
PGK-Cre cassette from pLL3.3;U6-sgKras/PGK-Cre was PCR-amplified with Q5®
polymerase (NEB), TOPO-cloned (Invitrogen), and verified by sequencing. To
generate the AAV-sgKras/Cre vector backbone, the sequence between the inverted
terminal repeats (ITRs) of a modified AAV2 transfer vector backbone plasmid was
removed using XhoI/SpeI69. Then, the U6-sgKras/PGK-Cre cassette was digested
from the TOPO vector with XhoI/XbaI and the 1.9-kb fragment was ligated into
the XhoI/SpeI-digested AAV2 backbone, destroying the SpeI site. A BGH polyA
sequence was inserted 3′ of Cre via MluI digestion. Lastly, a 2-kb homology arm
was generated from the region surrounding exon 2 of murine Kras via PCR
amplification (forward primer: GCCGCCATGGCAGTTCTTTTGTATC-
CATTTGTCTCTTTATCTGC; reverse primer: GCCGCTCGAGCTCTTGTGTG-
TATGAAGACAGTGACACTG). The amplicon was subsequently cloned into a
TOPO vector (Invitrogen). AvrII/BsiWI sites were introduced into the TOPO-
cloned 2-kb Kras fragment using Q5® site-directed mutagenesis (NEB) (AvrII
forward primer: TGAGTGTTAAAATATTGATAAAGTTTTTG; AvrII reverse
primer: CCTagGTGTGTAAAACTCTAAGATATTCC; BsiWI forward primer:
CTTGTAAAGGACGGCAGCC; BsiWI reverse primer: CGtACGCAGACTGTA-
GAGCAGC; restriction sites are underlined with mismatching bases in lowercase).
The Kras fragment harboring AvrII/BsiWI sites was released from TOPO with
NcoI/XhoI and ligated into NcoI/XhoI-digested AAV-sgKras/Cre to produce the
final AAV-KrasHDR/sgKras/Cre backbone vector.
To generate the control AAV-KrasHDR backbone without the sgRNA targeting
Kras, PGK-Cre was excised from a TOPO clone with NotI/XbaI and ligated into the
NotI/XbaI-digested modified AAV2 plasmid backbone. A BGH polyA sequence
and the mouse Kras homology arm were added as described above to produce the
control AAV-KrasHDR/Cre backbone vector.
To introduce a library of activating single point mutations and a DNA barcode
into the KrasHDR sequence of the AAV backbones, we synthesized four separate
295 bp Kras fragments with a degenerate “N” base (A, T, C, or G) at each of the
first two basepairs of Kras codons 12 or13 (Integrated DNA Technologies)
(Supplementary Fig. 1b). By design, each of the four fragment pools consisted of
three non-synonymous, single nucleotide mutations at codons 12 and 13 as well as
the wild-type Kras sequence to serve as a control. Thus, since each of the four pools
contained wild-type fragments, the overall representation of wild-type Kras alleles
was expected to be approximately four times higher than each of the mutant Kras
alleles. The synthesized fragments also contained silent (synonymous) mutations
within the sgKras target sequence and the associated PAM* to render the HDR
template resistant to Cas9-mediated editing. Additionally, an eight-nucleotide
random barcode was engineered into each fragment by introducing degenerate
bases into the wobble positions of the downstream Kras codons to enable
individual tumor barcoding (Supplementary Fig. 1b). Finally, each fragment
included flanking AvrII and BsiWI restriction sites for cloning into the AAV-
KrasHDR backbones (Supplementary Fig. 1b).
The four synthesized fragment pools were combined at equal molar ratios and
PCR-amplified (forward primer: CACACCTAGGTGAGTGTTAAAATATTG;
reverse primer: GTAGCTCACTAGTGGTCGCC). Amplicons were digested with
AvrII/BsiWI, purified by ethanol precipitation, and ligated into both AAV-KrasHDR
backbones (Supplementary Fig. 1c). Each ligated plasmid library was transformed
into Stbl3 electro-competent cells (NEB) and plated onto 20 × 10 cm LB-Amp
plates, which generated ~3 × 105 bacterial colonies per library. Colonies were
scraped into LB-Amp liquid media and expanded for 6 h at 37 °C to increase
plasmid yields to obtain enough plasmid DNA for AAV production. Plasmid DNA
was then extracted from bacterial cultures using an endotoxin-free Maxiprep kit
(Qiagen).
To determine the representation of each Kras variant and the distribution of
barcode nucleotides within each AAV plasmid library, purified AAV plasmid
libraries were PCR-amplified with primers tailed with Illumina® adapters
(lowercase) containing multiplexing tags (underlined N′s) (forward primer:
aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatctCTGCTGAAAATGACT
GAGTATAAACTAGTAGTC; reverse primer: caagcagaagacggcatacgagatNNNNNN
gtgactggagttcagacgtgtgctcttccgatcCTGCCGTCCTTTACAAGCGTACG), and then
deep-sequenced on a MiSeq sequencer (Illumina®). The universal bases between
Kras codon 12 and the barcode region were used to filter proper MiSeq reads. The
specific Kras codon 12 or 13 sequence and random barcode associated with each
read was then cataloged to determine the representation of the Kras variants and
the distribution of barcode nucleotides within each AAV plasmid library.
Availability of AAV-KrasHDR/sgKras/Cre vectors. A uniquely barcoded AAV-
KrasHDR/sgKras/Cre plasmid vector for each of the 13 KrasHDR alleles is available
from Addgene (#99848-99860).
Analysis of lung transduction by AAV capsid serotypes. Recombinant ssAAV-
GFP vectors were produced using a Ca3(PO4)2 transient triple transfection protocol
with pAd5 helper, pAAV-RSV-GFP transfer vector, and pseudotyping plasmids for
each of nine capsids of interest: AAV1, 2, 3b, 4, 5, 6, 8, 9_hu14, and DJ. Vector lots
were produced in HEK293T cells (ATCC) followed by double cesium chloride
density gradient purification and dialysis as previously described70. Recombinant
AAV vector preparations were titered by TaqMan quantitative PCR (qPCR) for
GFP (forward primer: GACGTAAACGGCCACAAGTT; reverse primer:
GAACTTCAGGGTCAGCTTGC; probe: 6-FAM/CGAGGGCGATGCCACC-
TACG/BHQ-1). To identify an optimal AAV serotype for adult lung epithelial cell
transduction, each mouse received 60 µL of pseudotyped AAV-GFP at maximal
titer via intratracheal administration (Supplementary Fig. 2). Mice were analyzed
5 days after AAV administration. Lungs were dissociated into single-cell suspen-
sions and prepared for FACS analysis of GFPpositive cells as described previously71.
GFPpositive percentages were determined by analyzing >10,000 viable (DAPInegative)
lung epithelial (CD45/Ter119/F4-80/CD31negative, EpCAMpositive) cells.
Production and titering of AAV-KrasHDR plasmid libraries. AAV libraries were
produced using a Ca3(PO4)2 triple transfection protocol with pAd5 helper, pAAV2/
8 packaging plasmid, and the barcoded Kras library transfer vector pools described
above. Transfections were performed in HEK293T cells (ATCC) followed by
double cesium chloride density gradient purification and dialysis as previously
described70. AAV libraries were titered by TaqMan qPCR for Cre (forward primer:
TTTGTTGCCCTTTATTGCAG; reverse primer: CCCTTGCGGTATTCTTTGTT;
probe: 6-FAM/TGCAGTTGTTGGCTCCAACAC/BHQ-1).
In vitro AAV/Cas9-mediated HDR. The nucleotide changes surrounding the
mutations at codon 12 and 13 (three nucleotide changes 5′ of codons 12/13 to
mutate the sgRNA recognition site and PAM motif, and up to 11 changes in the
barcode sequence) made it unlikely that the point mutations at Kras codons 12 and
13 would differentially affect the rate of HDR. We nevertheless tested whether
HDR efficiency might be influenced by differences in the sequence of individual
KrasHDR alleles. To induce in vitro AAV/Cas9-mediated HDR, we transduced LSL-
YFP;Cas9 cells with the purified AAV-KrasHDR/sgKras/Cre library (Fig. 2d). Cells
were maintained in cell culture media with 10 µM SCR7 (Xcessbio), an inhibitor of
non-homologous end joining (NHEJ), to promote HDR. Ninety-six hours after
transduction, genomic DNA was isolated from the LSL-YFP;Cas9 cells by phenol/
chloroform extraction followed by ethanol precipitation. The Kras locus was
amplified using a PCR strategy we developed for the specific amplification of
KrasHDR alleles integrated into the endogenous Kras locus (Fig. 2e). We then deep-
sequenced these amplicons to determine the representation of KrasHDR alleles
following in vitro HDR (see the “Illumina® library preparation and sequencing of
tumor barcodes from bulk tissue” section below for details on PCR and sequencing;
Fig. 2d–f).
Tumor initiation in mice using AAV/Cas9-mediated HDR. Lkb1flox(L), p53flox
(P), R26LSL-tdTomato (T), H11LSL-Cas9, and KrasLSL-G12D(K) mice have been pre-
viously described9,19–22. AAV administration by intratracheal inhalation to initiate
lung tumors (Fig. 3a and Supplementary Fig. 3a), retrograde pancreatic ductal
injection to initiate pancreatic tumors (Fig. 4a and Supplementary Fig. 7a), and
intramuscular gastrocnemius injection to initiate sarcomas (Fig. 5a and Supple-
mentary Fig. 8a) were performed as described19,43,72. Lung tumors were initiated in
PT;H11LSL-Cas9, LT;H11LSL-Cas9, and T;H11LSL-Cas9 mice with 60 µL of AAV-
KrasHDR/sgKras/Cre (1.4 × 1012 vector genomes/mL (vg/mL)), in PT, LT, and T
mice with 60 µL of AAV-KrasHDR/Cre (2.4 × 1012 vg/mL), or in KPT and KLT mice
with 60 µL AAV-KrasHDR/sgKras/Cre (1.4 × 1012 vg/mL) diluted 1:10,000 in 1×
PBS. Pancreatic tumors were initiated in PT;H11LSL-Cas9 mice with 100–150 µL of
AAV-KrasHDR/sgKras/Cre (1.4 × 1012 vg/mL) or in PT mice with 100–150 µL of
AAV-KrasHDR/Cre (2.4 × 1012 vg/mL). A 1:10 dilution of AAV-KrasHDR/sgKras/
Cre in 1× PBS was also administered to the lungs or pancreata of mice where
indicated. Sarcomas were initiated in the gastrocnemii of PT;H11LSL-Cas9 mice with
30 µL of AAV-KrasHDR/sgKras/Cre (5.2 × 1012 vg/mL). Sample sizes were chosen
based on previous studies from our group and others using virally induced mouse
models of cancer, and accounting for the anticipated rate of AAV/Cas9-mediated
HDR. Male and female mice were distributed as evenly as possible across experi-
mental cohorts, though littermates were otherwise randomly assigned. Following
viral transduction, mice were analyzed when they displayed symptoms of tumor
development. Within practical limitations, investigators were blinded to mouse
cohort assignments when performing all downstream analyzes up to sequencing
data analysis. The Institutional Animal Care and Use Committee of Stanford
University approved all mouse procedures.
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Analysis of individual lung tumors. Lung tumor-bearing mice displaying
symptoms of tumor development were analyzed 4–10 months after viral admin-
istration. Lung tumor burden was assessed by lung weight and quantification of
macroscopic Tomatopositive tumors under a fluorescence dissecting scope as indi-
cated (Fig. 3b, c and Supplementary Fig. 3b–e) (a single LT;H11LSL-Cas9 mouse had
minimal Tomatopositive signal that was restricted to a small region of one lung lobe,
indicative of improper intratracheal administration of AAV, and was therefore
removed from the study). The largest individual lung tumors that were not visibly
multifocal were dissected from bulk lungs under a fluorescence dissecting micro-
scope for sequencing. For the majority of lung tumors, Tomatopositive (and DAPI/
CD45/CD31/F4-80/Ter119negative) cancer cells were purified using FACS instru-
ments (Aria; BD Biosciences) within the Stanford Shared FACS Facility. Several
individually dissected tumors were not purified by FACS. Lung lobes from mice of
each genotype were also collected for histological analyses.
Analysis of individual pancreatic tumor masses. Pancreatic tumor-bearing mice
displayed symptoms of tumor development and were analyzed 3–4 months after
viral administration. Since pancreatic tumors generally appeared to be multifocal
(Supplementary Fig. 7b), individual regions of the pancreas containing
Tomatopositive tumor masses were dissected and FACS-purified for sequencing (a
mouse treated with a 1:10 dilution of AAV-KrasHDR/sgKras/Cre library also
developed pancreatic tumor masses and therefore was included in these analyses).
Regions of several pancreata were kept for histological analyses (Fig. 4b, c and
Supplementary Fig. 7c).
Analysis of individual sarcomas. Sarcoma-bearing mice with obvious tumor
development were analyzed 3–7 months after viral administration (Fig. 5 and
Supplementary Fig. 8). A region of each sarcoma was sequenced and an adjacent
region was saved for histological analysis (Fig. 5b, c and Supplementary Fig. 8c).
Characterization of Kras alleles in individual tumors. Genomic DNA for
sequencing was extracted from FACS-purified tumor cells and unsorted tumor
samples with a DNeasy Blood and Tissue Extraction kit (Qiagen). To identify Kras
point mutations and tumor barcodes, we PCR-amplified and sequenced the
KrasHDR alleles using two protocols optimized for several variables including
annealing temperature, extension time, and primer sequences: (1) forward primer:
CTGCTGAAAATGACTGAGTATAAACTAGTAGTC, reverse primer: AGCAGT
TGGCCTTTAATTGGTT, sequencing primer: AATGATACGGCGACCACCGA-
GATCTACAC, annealing temperature: 66 °C, extension time: 2–3 min; and (2)
forward primer: GCTGAAAATGACTGAGTATAAACTAGTAGTC, reverse pri-
mer: TTAGCAGTTGGCCTTTAATTGG, sequencing primer: GCACGGATGG-
CATCTTGGACC, annealing temperature: 64 °C, extension time: 2–3 min. These
protocols were used to specifically amplify integrated KrasHDR alleles from indi-
vidual tumors as each incorporated a forward primer overlapping the engineered
mutations in the PAM region upstream of codons 12 and 13, and a reverse primer
outside the homology arm. Long extension times (2–3 min) were used to enable
amplification of all KrasHDR alleles, even those containing insertions or duplica-
tions in intron 2 of the Kras locus (Supplementary Fig. 5d).
A variety of HDR-induced oncogenic Kras alleles were identified in 49
individual lung tumors (Fig. 3h), 4 individual pancreatic tumor masses (Fig. 4e),
and 5 sarcomas (Fig. 5e). For the KrasHDR alleles identified, p values for likelihood
of enrichment relative to WT (taking into account the initial representation of each
KrasHDR alleles in the AAV-KrasHDR/sgKras/Cre plasmid library) were generated
using a Fisher’s exact test, generalized for structural zeros when no tumors with a
WT KrasHDR alleles were identified (Fig. 3h)73. All p values were Bonferroni-
corrected for the number of variants investigated and were two-sided.
Apart from introducing the desired point mutations into the endogenous Kras
locus via HDR, targeting Kras exon 2 using CRISPR/Cas9 was also expected to
result in indels at the cut site following DNA repair by NHEJ instead of HDR. To
characterize these modifications, we used a generic PCR protocol to amplify both
Kras alleles (forward primer: TCCCCTCTTGGTGCCTGTGTG; reverse primer:
GGCTGGCTGCCGTCCTTTAC; sequencing primer: CAAGCTCATGCGGGTGT
GTC; annealing temperature: 72 °C). A spectrum of insertions and deletions at the
expected target site in the endogenous Kras locus was identified in 46 lung tumors
using this approach (Supplementary Fig. 6).
For some individual tumor samples, the sequence of both Kras alleles was not
immediately obvious following the above PCR and sequencing strategies. PCR
products from these complicated samples were TOPO-cloned (Invitrogen) and
transformed, and several colonies from each sample were plasmid-prepped and
sequenced to characterize both Kras alleles in each tumor. This approach was
reproducible and reliable across both biological and technical replicates.
These analyses uncovered several unexpected features in some Kras alleles from
individual lung tumors. Three distinct missense mutations at codon 24 (I24L, I24N,
I24M) were observed in a small subset of the individual lung tumors analyzed.
Further analyses indicated that these mutations were likely SNPs present in some of
the genetically engineered mice. The function of these alterations, if any, is
unknown.
Furthermore, we initially anticipated that recombination of the KrasHDR
template into the endogenous Kras locus would almost exclusively occur outside
the AvrII and BsiWI sites engineered into the KrasHDR template (Supplementary
Fig. 1d). However, the AvrII site, engineered by altering 2 base pairs 97 bp
upstream of exon 2, was absent in 5 out of 25 tumors in which we directly analyzed
this region of the KrasHDR allele (Supplementary Fig. 5c). The BsiWI site,
engineered by altering 1 base pair 20 bp downstream of exon 2, was absent in 11
out of 58 tumors (Supplementary Fig. 5c). These findings indicated that while
recombination of the KrasHDR template most often occurred within the larger,
more distal homology arms, it also occurred at a detectable frequency within very
short regions of homology flanked by 5′ and 3′ mismatches (including the PAM*
mutations, a Kras codon 12 or 13 mutation, and up to 11 mismatches within the
barcode region).
After we initially identified the presence of duplications in KrasHDR alleles in
some tumors (Supplementary Fig. 5d), we designed PCR primers to specifically
amplify duplications of Kras exon 2 that occurred on either side of exon 2 within
KrasHDR alleles (right-hand duplication—forward primer: TGACCCTAC
GATAGAGGTAACG; reverse primer: CTCATCCACAAAGTGATTCTGA;
sequencing primer: TGACCCTACGATAGAGGTAACG; left-hand duplication—
forward primer: TGAGTGTTAAAATATTGATAAAGTTTTTG; reverse primer:
TCCGAATTCAGTGACTACAGATG; sequencing primer: TGAGTGTTAAA
ATATTGATAAAGTTTTTG). Each of these duplication-specific PCR protocols
used adjacent primer pairs in opposite orientations, ensuring that amplification
would only occur if a duplication were present. Duplications of varying lengths
were identified, including duplications of the second half of wild-type exon 2 or the
entire exon 2 (but lacking critical regions of the splice acceptor) (Supplementary
Fig. 5d). Deletions and duplications of regions of intron 2 were also observed.
Furthermore, we observed integrations of parts of the AAV transfer vector,
including the U6 promoter and viral ITR, into intron 2. Given the size and location
of these alterations, none would be expected to change splicing of Kras mutant
exon 2 to exon 3, consistent with the requirement of oncogenic Kras to drive
tumorigenesis.
Generating a normalization control for Tuba-seq. To obtain a normalization
control for tumor barcode sequencing, a single large tumor was dissected from an
PT;H11LSL-Cas9 mouse, digested into a single cell suspension, and plated to generate
a cell line. After expanding these cells and then extracting genomic DNA, Kras
exon 2 was PCR-amplified (forward primer: TCCCCTCTTGGTGCCTGTGTG;
reverse primer: GGCTGGCTGCCGTCCTTTAC). The PCR product was
sequenced (using specific and generic sequencing primers described above) to
confirm the presence of a KrasHDR allele and a barcode. A single KrasG12V allele
(GTT) with a unique barcode (CGGGAAGTCGGCGCTTACGATC) was identi-
fied. Genomic DNA from this cell line was used as a normalization control for
high-throughput sequencing for all bulk lung samples (Supplementary Fig. 9b).
Bulk lung tissue processing and DNA extraction. Bulk lung samples were dis-
sected from virally-transduced mice and stored at −80 °C prior to processing. To
extract genomic DNA for sequencing, samples were thawed and transferred to
50 mL conical tubes. 20 mL of lysis buffer (100 mM NaCl, 20 mM Tris pH 7.6,
10 mM EDTA pH 8.0, 0.5% SDS in H2O) plus 200 µL proteinase K (20 mg/mL)
were added to each sample. Next, 3 µg (~5 × 105 genomes) of normalization control
DNA was added to each sample (Fig. 6a and Supplementary Fig. 9b). Samples were
then carefully homogenized using a tissue blender, which was cleaned between each
sample by progressing through clean 10% bleach, 70% ethanol, and 1× PBS.
Homogenized samples were lysed at 55 °C overnight. Genomic DNA was isolated
from tissue lysates by phenol/chloroform extraction followed by ethanol
precipitation.
Bulk pancreatic tissue processing and DNA extraction. Pancreatic tumor
masses were dissected and digested, and viable neoplastic cells (Tomatopositive,
DAPI/CD45/CD31/Ter119/F4-80negative) were isolated by FACS. No normalization
control was added to the pancreatic cancer samples. Genomic DNA was isolated
from FACS-isolated neoplastic cells using a DNeasy Blood and Tissue Extraction
kit (Qiagen), and then further purified by ethanol precipitation.
Illumina® library preparation and Tuba-seq. To uncover the number and size of
tumors harboring each Kras variant in a massively parallel and quantitative
manner, we developed a two-round PCR strategy that enabled multiplexed Illu-
mina® sequencing of barcoded KrasHDR alleles (Fig. 2e). For the first round of PCR,
we used a forward primer complementary to the KrasHDR sequence containing the
three PAM and sgRNA target site mutations (PAM*; bold in the first round for-
ward primer sequence) (first round forward primer: GCTGAAAATGACTGAG-
TATAAACTAGTAGTC), and a reverse primer complementary to a downstream
region of the endogenous Kras locus not present in the HDR template of the AAV-
KrasHDR/sgKras/Cre vector (first round reverse primer: TTAGCAGTTGGCCTT-
TAATTGG). This primer pair was chosen to specifically amplify genomic KrasHDR
alleles without amplifying the abundant wild-type Kras alleles or potential episomal
AAV-KrasHDR/sgKras/Cre vectors present in DNA purified from bulk tumor-
bearing tissue. Additionally, a P5 adapter (italicized), an 8 bp custom i5 index (N′s),
and an Illumina® sequencing primer sequence (read 1) (underlined) were included
at the 5′ end of the first round forward primer to enable multiplexed Illumina®
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sequencing (first round forward primer for Illumina® sequencing: AATGA-
TACGGCGACCACCGAGATCTACACNNNNNNNNACACTCT
TTCCCTACACGACGCTCTTCCGATCTGCTGAAAATGACTGAGTA-
TAAACTAGTAGTC).
Importantly, since the characterization of KrasHDR alleles in individual tumors
uncovered some variability in HDR (e.g., diverse indels in Kras intron 2;
Supplementary Fig. 5), only four cycles (for lung samples) or six cycles (for
pancreas samples) were performed in the first round of PCR to minimize the
potential for bias during the amplification of products of variable length.
Furthermore, a high-efficiency polymerase (Q5® hot start high-fidelity polymerase,
NEB; 64 °C annealing temperature) and a long extension time (3:00 min) were used
to ensure robust amplification of all KrasHDR alleles. KrasHDR alleles in genomic
lung DNA were amplified using between 4 and 40 separate 100-µL PCR reactions
and then pooled following amplification to reduce the effects of PCR jackpotting
(Supplementary Fig. 9a). Each of these 100-µL PCR reactions contained 4 µg of
DNA template to amplify from a large initial pool of KrasHDR alleles. Following the
first round of amplification, all replicate PCR reactions were pooled and 100 µL of
each sample was cleaned up using a QIAquick PCR purification Kit (Qiagen).
Purified first round PCR amplicons were used as template DNA for a 100 µL
second round Illumina® library PCR (Q5® hot start high-fidelity polymerase, NEB;
72 °C annealing temperature; 35 cycles for lung samples, 40 cycles for pancreas
samples). The second round of PCR amplified a 112 bp region entirely within the
Kras exon 2 sequence present in first round PCR amplicons. The second round
reverse primer contained a P7 adapter (italicized), a reverse complemented 8 bp
custom i7 index (“Ns”), and a reverse complemented Illumina® sequencing primer
sequence (read 2) (underlined) at the 5′ end to enable dual-indexed, paired-end
sequencing of Illumina® libraries (second round reverse primer #1:
CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGACTTCAGAC
GTGTGCTCTTCCGATCCGTAGGGTCATACTCATCCACA). The second round
PCR forward primer was complementary to the P5 Illumina® adapter added to the
amplified KrasHDR allele by the forward primer during the first round PCR (second
round forward primer: AATGATACGGCGACCACCGAGATCTACAC). This
primer was used to amplify first round PCR amplicons without amplifying any
contaminating genomic DNA that may have been carried over from the first round
PCR reaction. Furthermore, a second reverse primer encoding the P7 adaptor
sequence was added to the second round PCR reaction at the same concentration
as the two other primers (second round reverse primer #2:
CAAGCAGAAGACGGCATACGAGAT). This primer binds the reverse
complemented P7 adaptor sequence added to the KrasHDR amplicons by second
round reverse primer #1. Since the second round PCR was performed over 35–40
cycles, the P7 adaptor (second round reverse primer #2) was added to limit the
amount of non-specific amplification produced by the lengthy second round
reverse primer #1.
After the second round of amplification, 100-µL PCR reactions were run on a
2.5% agarose gel and a band of the expected size was excised. PCR amplicons were
extracted from gel fragments using a QIAquick gel extraction Kit (Qiagen). The
size, concentration, and purity (i.e., the lack of unexpectedly sized peaks indicative
of nucleic acid or buffer contaminants) of the purified Illumina® libraries was
confirmed using a Bioanalyzer (Agilent). Individual Illumina® libraries with unique
dual-indices were then pooled together such that libraries originally derived from
mice with greater tumor burden were represented at a higher ratio in the final pool
than those from mice with lower tumor burdens (Supplementary Fig. 9a). A total of
35 individual samples were combined into two Illumina® library pools. The size,
concentration, and purity of each pool was again confirmed on a Bioanalyzer
(Agilent). Each final Illumina® library pool was then deep-sequenced on an
Illumina® HiSeq lane using a multiplexed, 150 bp paired-end Rapid Run
sequencing program (Elim Biopharmaceuticals).
Estimating the size and number of barcoded tumors. We developed a publically
available pipeline to call tumors from our de-multiplexed Illumina® sequencing
data, termed Tuba-seq (https://github.com/petrov-lab/tuba-seq). The pipeline tal-
lies unique barcode sequences and eliminates recurrent sequencing errors using an
algorithm designed to denoise deep-sequencing data of amplicons (DADA2)74. We
tailored this algorithm to minimize the occurrence of spurious tumor calls, and
minimize technical biases (including variation in read depth, variation in Illumina®
sequencing machine error rates, and variation in barcode diversity). This pipeline
was modified here for the analysis of tumor genotypes and barcodes following
AAV/Cas9-mediated somatic HDR-driven tumorigenesis, as described below.
Although our Illumina® sequencing libraries contained a small 112 bp fragment
of the KrasHDR alleles, we performed 150 bp paired-end sequencing of these
fragments and merged the overlapping forward and reverse reads to reduce the
likelihood of Illumina® sequencing errors in Kras codons 12 and 13 and the
barcode region of the KrasHDR alleles. Overlapping paired end-reads were merged,
quality-filtered, and trimmed using PANDAseq (fragment length: 60 bp; forward
trimming primer: ATGACTGAGTATAAACT; reverse trimming primer:
CTCATCCACAAAGTGA)75.
Even after merging forward and reverse reads to reduce sequencing errors, an
average of ~1 error per 10,000 bases was detected, presumably from recurrent
Illumina® sequencing errors or from errors introduced during PCR. Given this
error rate, we expected that reads from a large, uniquely barcoded tumor
containing single nucleotide mismatches would be called as small, spurious tumors
of ~1/10,000th the size of the large real tumor. Even without Tuba-seq, this
phenomenon was discernible by eye, as we observed small clusters of spurious
“tumors” that were ~3–4 orders of magnitude smaller and contained 1 nucleotide
deviation relative to the largest tumor in specific mice. Additionally, each KrasHDR
variant-barcode pair also possessed recurrent sequencing errors in mutant base in
oncogenic Kras codon 12 or 13.
To accurately call tumors, we developed a computational and statistical pipeline
for the analysis of tumor barcode sequencing data. We first estimated the residual
rate of sequencing/PCR errors from the seven nucleotides upstream of Kras codon
12 and the seven nucleotides downstream of the final barcode base. We then used
our model of sequencing errors to cluster unique read pileups (truncated to within
seven nucleotides of the barcoded bases) into unique tumors via DADA2. A
minimum confidence in unique origin of the clusters of 0.01 (i.e., omega_a= 0.01)
was used. A larger threshold increased the number of unique tumors called in a
mouse sample. We chose this larger value rather than those used previously26, as
paired-end sequencing gave us greater confidence that unique read pileups were
truly distinct tumors. For example, we found that this threshold eliminated all
unintended read sequences (e.g., reads with inappropriate nucleotides outside of
the barcode), and that this threshold called a total number of lesions within each
mouse more consistently between biological replicates. These were important
considerations since without proper handling of read errors, the number of called
tumors can positively correlate with sequencing read depth. Finally, we removed
any tumors with DNA sequences that deviated by only 1 nucleotide from a lesion
that was 10,000× larger. This affected only 1.56% of tumor calls.
After generating the read pileups and performing the corrections described
above, we normalized the number of reads from each called tumor to the number
of reads from the normalization control that was spiked into each sample prior to
DNA extraction from bulk tumor-bearing tissue lysates (Fig. 6a and Supplementary
Fig. 9b). This allowed us to generate a reasonable estimate of the number of
neoplastic cells in each tumor and allowed us to merge data from mice of the same
genotype and treatment. However, there are several factors that impact our ability
to accurately quantify the absolute number of neoplastic cells within each tumor.
First, some KrasHDR alleles in individual tumors harbored insertions or
deletions in Kras intron 2, inside the first round PCR primers for Illumina®
sequencing. Although the presence of different sized amplicons could generate a
PCR bias, we attempted to reduce this by performing only four to six cycles in the
first round of Illumina® library PCR, using a long extension time (~3 min), and
using a fast (20–30 s/kb), high fidelity polymerase (Q5®; NEB). As the final
Illumina® library PCR product in the second round of amplification is short and
uniform across all samples, PCR amplification should not be biased at this step.
Second, given that the Kras variants and barcodes are knocked into the
endogenous Kras locus, it is possible that in some tumors this region is genomically
amplified (which has been documented in KrasG12D-driven lung tumors initiated in
mouse models of lung cancer31,76). Although Kras amplifications do not typically
result in very high Kras copy numbers, any amplification of this region would lead
to an overestimation of the number of neoplastic cells in tumors with amplified
KrasHDR alleles since our conversion from read count to cell number assumes that
each cell contains a single copy of the barcoded KrasHDR allele.
Lastly, the normalization control itself was generated from cells from a tumor
with a known duplication in Kras intron 2, which produces a larger PCR product in
the first round of the Illumina® library preparation than tumors without a
duplication. Thus, any PCR bias away from the KrasHDR allele in the normalization
control would result in a systematic overestimation of the size of tumors.
Sequencing of tumor barcodes from 35 samples on two lanes of an Illumina®
Hi-Seq Rapid Run, combined with our analysis pipeline, enabled the detection of
unique barcodes with read counts covering five orders of magnitude. Thus, the
resolution of this approach enables detection of both large lesions and small
hyperplasias within bulk tissue. However, the ability to detect a large numbers of
lesions within bulk tissue increases the probability of barcode collisions: the
occurrence of two or more lesions with the same DNA barcode in the same mouse.
Barcode collisions can overstate the size of observed tumors because two small
“colliding” tumors would be identified as a single, larger tumor. Therefore, we
developed a statistical model of barcode collisions to reduce this likelihood and not
overtly bias the estimated sizes of called tumors.
Our model of barcode collisions accounts for the likelihood pi of observing each
of the 24,576 possible barcodes i for each Kras variant in our study. A majority of
the reproducible variation between barcode frequencies in our pool derives from
statistically independent variation in the nucleotide frequencies at each wobble base
(i.e., each barcode is not equally likely in the pool because there was subtle variation
in nucleotide concentrations during synthesis of the barcodes fragments) (Fig. 2c).
Thus, we estimate the independent frequency fb,n of each nucleotide n at every base
b in the barcode and use this data to predict barcode likelihoods based on each
barcode’s sequence Bi,b,n (where B is 1 if barcode i possesses nucleotide n at
position b and 0 otherwise) as follows:
pi ¼
Y
b
Bi;b;n  fbn
Here, superscript indices represent contravariant vectors and the dot represents
matrix multiplication. This model predicts every barcode’s frequency with only 21
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free parameters. Because some residual over-representation of barcodes persisted in
the lung samples, we discarded the 10% most frequently observed barcodes, after
correcting for nucleotide frequencies, from all lung analyses. These most frequently
observed barcodes were identified independent of our mouse experiments by
Illumina® sequencing (MiSeq) of our pAAV-KrasHDR/sgKras/Cre plasmid pool
prior to viral production. After this processing, we then renormalized ∑ipi to one.
We then assumed that the occurrences of each barcode within each mouse was
a multinomial sampling process. The mean number of collisions Ci for each
observed barcode within each mouse is then:
Ci pi;Nð Þ ¼
P1
k¼1
k 1ð ÞP k; pi;Nð Þ
¼ μi  P k ¼ 0; pi;Nð Þ  1
¼ Npi þ 1 pið ÞN  1
Here, μi denotes the mean number of barcodes within each mouse, while N denotes
the total number of tumors (both unknowns). N is then determined from the
observed number of tumors in each mouse N(obs) using the equation
NðobsÞ ¼ N Pi Ci pi;Nð Þ, which is solved using Brent’s Method.
This model found that barcode collisions were generally rare in our mouse
samples (on average 4.04%). However, the likelihood of collisions can vary by
mouse and by Kras variant. For example, the average predicted number of
collisions for WT KrasHDR alleles was 5.8% and as high as 12% in one mouse. WT
KrasHDR alleles were expected to experience the highest number of collisions since
WT Kras vectors were intentionally represented approximately fourfold more than
each mutant Kras vector in the initial pAAV-KrasHDR/sgKras/Cre plasmid pool
(Fig. 2b). Thus, we divided the size of each lesion by 1 + Ci to minimize the bias
that barcode collisions impart on tumor size distributions. Because collisions are
rare events, the particular number of collisions within each mouse can differ
substantially from Ci. Because of this limitation, we believe that this correction
minimizes systematic bias in tumor size distributions resulting from barcode
collisions that would alter our final estimates of the mean effect of each Kras
variant; however, it cannot effectively identify the specific collisions that occurred
among specific barcodes in specific mice.
To determine whether Kras variants had quantitatively different abilities to
drive tumorigenesis, we elected to focus on lung tumors estimated to contain
> 100,000 neoplastic cells (i.e., one-fifth the “size” of the normalization control
DNA added to each sample, which was derived from ~5 × 105 cells). Regression
analysis of lung tumors above this cell number from replicate samples
(independent sample preparation, sequencing, and processing) demonstrated high
correlation (all R2 values were above 0.99; Supplementary Fig. 10). We believed that
the estimated number of cells in tumors below this cutoff was less reliable; KrasHDR
variant-barcode pairs present at low read counts were much more likely to be
biased by barcode collisions and variability in both PCR amplification and DNA
sequencing. Additionally, we could not rule out the possibility that these variant-
barcode pairs were a product of off-target amplification of our AAV-KrasHDR/Cre
control vector, which contains a longer KrasHDR template that partially overlaps
the reverse primer used for Illumina® library preparation of bulk samples with
AAV-KrasHDR/sgKras/Cre-initiated tumors (as opposed to small but real HDR-
initiated lung hyperplasias). We anticipate that future technical and computational
improvements will further improve the resolution of this pipeline and enable
tumor calling at much smaller cell number cutoffs.
Since Kras expression can be influenced by overall changes in codon usage that
effect tumorigenesis46,47, we also determined whether the use of different
nucleotides in the barcode region of KrasHDR alleles had a detectable effect on lung
tumor size. To do this, we calculated the relative change in codon usage generated
by the unique barcode in each lung tumors. The barcode region of each KrasHDR
allele contains three anchor bases that are different from wild-type Kras (but
universal to all KrasHDR alleles), as well as random nucleotides in the eight
positions that make up the barcode. A “codon usage score” for the KrasHDR allele
in each lung tumor was calculated as the sum of the mouse codon frequencies
(from a publicly available mouse codon usage table48) across the 22 bp barcode
region. A codon usage score was also calculated for wild-type Kras and for a
“minimal KrasHDR allele” containing the three universal anchor bases, but wild-
type bases at all eight positions of the barcode (Supplementary Fig. 12).
Analysis of sequencing data from bulk tumor-bearing lungs. We quantified the
relative number of tumors harboring each Kras variant by counting tumors above
100,000 cells in six PT;H11LSL-Cas9, six LT;H11LSL-Cas9, and three T;H11LSL-Cas9
mice (Supplementary Fig. 9a). Read counts from tumors with each Kras variant
were normalized by dividing by the initial representation of each variant in the
AAV-KrasHDR/sgKras/Cre plasmid pool (for this analysis, the initial representation
of each variant in the plasmid pool was calculated from the total number of reads
associated with each Kras variant after removing barcodes above the 98th per-
centile of barcode abundance; this restriction did not appreciably alter results, and
was simply applied to ensure that extremely abundant variant-barcode pairs did
not overtly impact the overall representation of specific variants).
Relative tumor number was then scaled such that WT Kras variants had a
representation of 1. A small number of WT KrasHDR alleles appeared to arise from
tumors above 100,000 cells. These could represent tumors in which an HDR event
created the non-oncogenic Kras WT genotype but which nonetheless evolved into a
tumor for other reasons, or the WT Kras variant “hitchhiked” with an oncogenic
Kras variant by co-incident HDR in the same lung cell followed by expansion
driven by the oncogenic variant.
A small number of residual cells from individual tumors dissected from bulk
tissue (and analyzed as described above) were usually detectable in our bulk tumor
sequencing data. In all analyses of tumor size, these dissected tumors were excluded
as we could not infer their true size. However, when analyzing the number of
tumors above 100,000 cells in each treated mouse genotype, we included data from
individually dissected tumors since dissectible tumors were always among the
largest tumors observed within any mouse and, therefore, certainly above the
100,000 cell threshold.
Statistically significant differences in tumor number were determined using
Fisher’s exact test. For each variant, two tests were performed, comparing with
either the frequency of G12D or WT KrasHDR alleles (Fig. 6b–e). All p values were
Bonferroni-corrected for the number of variants investigated and were two-sided.
A two-sided “many cells” Pearson’s χ2 test was used to compare the distribution of
tumor numbers across all Kras variants in PT;H11LSL-Cas9 and LT;H11LSL-Cas9 mice
relative to T;H11LSL-Cas9 mice (Supplementary Fig. 11f).
Analysis of sequencing data from bulk pancreas tumor masses. Following
Illumina® sequencing and read processing as described above, we quantified the
number of pancreatic tumors with each KrasHDR allele in four primary tumor
masses and three metastasis samples from two PT;H11LSL-Cas9 mice transduced
with AAV-KrasHDR/sgKras/Cre by retrograde pancreatic ductal injection (Sup-
plementary Fig. 13a). Since we did not add normalization control DNA to these
samples, we used a stringent internal read count cutoff of two times the most
abundant WT KrasHDR allele in each sample. Combined with the four tumors
identified by individual pancreatic tumor analysis (Fig. 4e), we identified 25 pri-
mary tumors containing KrasHDR alleles across three PT;H11LSL-Cas9 mice. One
KrasHDR allele with a specific variant-barcode pair was identified in an individually
dissected tumor as well as in the bulk tumor mass from the same mouse and was
therefore only counted once. Two KrasHDR alleles with specific variant-barcode
pairs were discarded since they were thought to be contamination from cell lines
generated from individual pancreatic tumors with the same specific variant-
barcode pairs. Tumor number counts for each KrasHDR allele were then normalized
to the initial representation of each allele in the AAV-KrasHDR/sgKras/Cre library.
Statistically significant differences in the number of tumors with each KrasHDR
allele were determined by a Fisher’s exact test for likelihood of enrichment relative
to WT (Fig. 7b). All p values were Bonferroni-corrected for the number of variants
investigated and were two-sided. Spatial and phylogenetic relationships between
primary tumors and metastases were established through shared KrasHDR variant-
barcode pairs (Fig. 7c and Supplementary 13b).
Comparing the oncogenicity and biochemistry of Kras variants. To identify any
relationships between the oncogenicity of Kras mutants observed in vivo and
differences in their biochemical properties, we compared our data to the bio-
chemical data for several of the KRAS variants reported in Hunter et al.2 (Sup-
plementary Fig. 14)48. Specifically, intrinsic and P120GAP-stimulated GTP
hydrolysis rates (Hunter et al.2; Supplementary Data 1), as well as relative RAF
kinase affinities (Hunter et al.2; Supplementary Data 2), were obtained for human
KRASG12D, KRASG12V, KRASG12R, KRASG12C, KRASG12A, and KRASG13D. Lung
and pancreatic tumor numbers plotted against this biochemical data are shown in
Supplementary Fig. 14.
Analysis of KRAS mutations in human cancer genomics data sets. The pre-
valence of KRAS mutations in human lung adenocarcinoma, PDAC, and rhab-
domyosarcoma was quantified from human cancer genomics data available in the
Catalog of somatic mutations in cancer (COSMIC; release v81) and the American
Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia
Information Exchange (GENIE; version 1.0.1) databases, as well as from other
independent studies, as outlined below (Supplementary Fig. 15 and Supplementary
Data 4). COSMIC mutation data from both targeted and genome-wide screens
were utilized (http://www.cancer.sanger.ac.uk/cosmic)77. The data were obtained,
in part, from cBioPortal78,79.
To determine the prevalence of KRAS mutations in human lung
adenocarcinoma, we compiled data from COSMIC and GENIE as well as several
additional studies (Supplementary Data 4)58,78,79. All samples were screened for
duplicates across databases by comparing sample identifier numbers. All remaining
samples were pooled to determine both the overall frequencies of somatic
mutations in KRAS and the spectrum of specific KRAS mutations observed in lung
adenocarcinoma (Supplementary Fig. 15a and Supplementary Data 4).
We also compared the spectrum of KRAS mutations in lung adenocarcinomas
in “never-smoker” and “current/former-smoker” patients from various studies
(Supplementary Fig. 16b and Supplementary Data 6). Patients whose smoking
history was unknown were not included in the analysis. “Never-smokers” included
patients that reported smoking fewer than 100 cigarettes in their lifetime as well as
patients described as “nonsmokers.” “Current/former-smokers” included patients
described as “former” or “current” smokers in the included studies, as well as
individuals described as “smokers.”
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To determine the prevalence of KRAS mutations in human PDAC, we
combined data from COSMIC and GENIE, as well as The Cancer Genome Atlas
(TCGA) provisional data set (NIH NCI Genomic Data Commons Release 7.0) and
one additional study50. We screened for duplicate samples by comparing sample
identifier numbers. All remaining samples were pooled to estimate the frequency of
somatic mutations in KRAS, as well as the spectrum of specific KRAS mutations in
patients with PDAC (Supplementary Fig. 15c and Supplementary Data 4).
To examine KRAS mutations in patients with rhabdomyosarcoma, we similarly
compiled data from COSMIC and GENIE, as well as from numerous independent
studies (Supplementary Data 4). We screened for duplicate samples by comparing
sample identifier numbers. Remaining samples were pooled to estimate overall
KRAS mutation frequency and the specific spectrum of KRAS mutations observed
in patients with rhabdomyosarcoma (Supplementary Fig. 15b and Supplementary
Data 4).
Approximating relative KRAS mutation frequencies. We approximated the
relative induction rate of mutations in KRAS codons 12 and 13 from data reported
in Campbell et al.58 Campbell et al.58 document six mutational signatures in lung
adenocarcinomas: a smoking-related signature (SI4), a molecular clock-like sig-
nature (SI5), an ultraviolet (UV)-related signature (SI7), a mismatch-repair sig-
nature, and two APOBEC-related signatures (SI13 and SI2). Since we were
interested in estimating the relative rate of induction of KRAS codons 12 and 13
mutations prior to tumorigenesis, we focused on the mutational processes pre-
sumed to be tumor-extrinsic—the smoking-related signature and the molecular
clock-like signature. Campbell et al.58 (Supplementary Data 7) contains the esti-
mated probabilities of every possible nucleotide substitution within each trinu-
cleotide motif (i.e., the substitution plus the adjacent 5′ and 3′ bases) for each of the
mutational signatures. To approximate the relative frequency of specific substitu-
tions in KRAS codons 12 and 13, we summed the trinucleotide substitution
probabilities associated with the smoking- and molecular clock-like signatures for
each of the KRAS mutations. Normalizing these probabilities within the 12 single-
nucleotide mutations in KRAS codon 12 or 13 allowed us to approximate their
average relative frequencies in the cells of origin of the lung adenocarcinomas
analyzed in Campbell et al. (Supplementary Data 6, current study). These relative
frequencies were used to normalize the human data in Supplementary Fig. 16a.
Comparison of mouse vs. human Kras. Coding and amino acid sequences for
mouse Kras (Kras_GRCm38.p4_CCDS20693.1) and human KRAS (Kras_GRCh38.
p7_CCDS8702.1) were downloaded from Ensembl (http://www.ensembl.org;
Release 89)80. Amino acid identity was assessed in a pairwise fashion across each of
the 188 amino acids of KRAS. Codon usage for each species was calculated using
publicly available codon usage tables48. The log-2 fold change in the usage of each
codon relative to average (i.e., 1/64) was calculated (Supplementary Fig. 17).
Data availability. All raw Illumina® sequencing data have been deposited in the
NCBI Sequence Read Archive (SRA) with study number SRP119241 (accesion
numbers for the raw sequencing files are SRR6124017–SRR6124051). Wherever
possible, the processed data used to generate graphs for Figures and Supplementary
Figures are also available in numerical form in the Supplementary Data files.
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